
Regeneron Pharmaceuticals Inc
NASDAQ:REGN

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
663.008
1 201.76
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Regeneron Pharmaceuticals Inc





In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases.
Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases.
Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.
Earnings Calls
Management

Dr. Leonard S. Schleifer, M.D., Ph.D., is the founder and longtime leader of Regeneron Pharmaceuticals, Inc., a biotechnology company dedicated to developing innovative medicines for serious diseases. Born in Queens, New York, he earned both his medical degree and Ph.D. in pharmacology from the University of Virginia. Dr. Schleifer launched Regeneron in 1988, driven by a passion for science and a commitment to address unmet medical needs. Under his leadership, Regeneron has grown from a small startup into a major player in the biotech industry, known for its development of groundbreaking therapies. Notably, Regeneron developed the first approved treatment for wet age-related macular degeneration and several other successful drugs across a range of therapeutic areas, including ophthalmology, oncology, and immunology. Dr. Schleifer is known for fostering a culture of scientific innovation that emphasizes rigorous research and development as the driving force behind the company's success. His tenure at Regeneron is marked by significant achievements in both drug discovery and corporate growth, earning him recognition as one of the industry's leading executives. In addition to his work at Regeneron, Dr. Schleifer has been involved in numerous industry and academic boards, contributing to the broader scientific and medical communities. His leadership and vision have been pivotal in positioning Regeneron as a leader in biopharmaceutical innovation.

Under his leadership, Regeneron has grown from a small startup into a major player in the biotech industry, known for its development of groundbreaking therapies. Notably, Regeneron developed the first approved treatment for wet age-related macular degeneration and several other successful drugs across a range of therapeutic areas, including ophthalmology, oncology, and immunology.
Dr. Schleifer is known for fostering a culture of scientific innovation that emphasizes rigorous research and development as the driving force behind the company's success. His tenure at Regeneron is marked by significant achievements in both drug discovery and corporate growth, earning him recognition as one of the industry's leading executives.
In addition to his work at Regeneron, Dr. Schleifer has been involved in numerous industry and academic boards, contributing to the broader scientific and medical communities. His leadership and vision have been pivotal in positioning Regeneron as a leader in biopharmaceutical innovation.

Dr. George D. Yancopoulos, M.D., Ph.D., is a prominent figure in the biotechnology industry, known for his integral role in the scientific leadership of Regeneron Pharmaceuticals, Inc. As the co-founder, President, and Chief Scientific Officer of the company, he has been instrumental in pioneering numerous scientific and therapeutic innovations. He completed his undergraduate studies in biochemistry and molecular biophysics at Columbia College and earned both his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos joined Regeneron in 1989 as its founding scientist and has since been a driving force in its growth and success. His leadership and vision have led to the development of key technologies and groundbreaking medications, including treatments for eye diseases, inflammatory conditions, cancer, and infectious diseases. Notably, he played a significant role in the invention of the groundbreaking VelociSuite® technologies, including VelocImmune®, which have been fundamental in developing several successful antibody therapies. Under his scientific direction, Regeneron has consistently been at the forefront of innovation in biotechnology and pharmaceuticals. Dr. Yancopoulos' work has earned him numerous accolades, and he is widely regarded as one of the most influential scientists in the industry. His contributions extend beyond his work at Regeneron, as he continues to be actively involved in advancing scientific research and mentoring the next generation of scientists.

Dr. Yancopoulos joined Regeneron in 1989 as its founding scientist and has since been a driving force in its growth and success. His leadership and vision have led to the development of key technologies and groundbreaking medications, including treatments for eye diseases, inflammatory conditions, cancer, and infectious diseases. Notably, he played a significant role in the invention of the groundbreaking VelociSuite® technologies, including VelocImmune®, which have been fundamental in developing several successful antibody therapies.
Under his scientific direction, Regeneron has consistently been at the forefront of innovation in biotechnology and pharmaceuticals. Dr. Yancopoulos' work has earned him numerous accolades, and he is widely regarded as one of the most influential scientists in the industry. His contributions extend beyond his work at Regeneron, as he continues to be actively involved in advancing scientific research and mentoring the next generation of scientists.

Dr. Andrew J. Murphy, Ph.D., is an esteemed scientist and executive with extensive experience in biomedical research and pharmaceutical development. He currently holds the position of Senior Vice President at Regeneron Pharmaceuticals Inc., a leading biotechnology company known for its work in developing a variety of therapeutics across numerous disease areas. Dr. Murphy's career at Regeneron has been marked by his significant contributions to the company's R&D efforts, particularly in the field of genetics and genomics. He is highly regarded for his work in understanding the genetic basis of disease and for driving innovative research programs that aim to translate genetic discoveries into new therapeutic strategies. His expertise has been instrumental in advancing Regeneron's pipeline of investigational drugs and therapeutic products. In addition to his role at Regeneron, Dr. Murphy is also recognized for his academic contributions. He holds a Ph.D. in a relevant scientific field and has been involved in numerous publications and presentations that outline advancements in genetic research and biotechnology. His leadership extends beyond his scientific acumen, as he plays a pivotal role in fostering collaborations with academic institutions, industry partners, and regulatory bodies to enhance the development and delivery of novel therapies. Dr. Murphy's work continues to contribute significantly to Regeneron's mission of delivering innovative medicines to patients with unmet medical needs. His dedication to science and medicine exemplifies the impact of leadership in driving forward the boundaries of what is possible in biopharmaceutical research and development.

Dr. Murphy's career at Regeneron has been marked by his significant contributions to the company's R&D efforts, particularly in the field of genetics and genomics. He is highly regarded for his work in understanding the genetic basis of disease and for driving innovative research programs that aim to translate genetic discoveries into new therapeutic strategies. His expertise has been instrumental in advancing Regeneron's pipeline of investigational drugs and therapeutic products.
In addition to his role at Regeneron, Dr. Murphy is also recognized for his academic contributions. He holds a Ph.D. in a relevant scientific field and has been involved in numerous publications and presentations that outline advancements in genetic research and biotechnology. His leadership extends beyond his scientific acumen, as he plays a pivotal role in fostering collaborations with academic institutions, industry partners, and regulatory bodies to enhance the development and delivery of novel therapies.
Dr. Murphy's work continues to contribute significantly to Regeneron's mission of delivering innovative medicines to patients with unmet medical needs. His dedication to science and medicine exemplifies the impact of leadership in driving forward the boundaries of what is possible in biopharmaceutical research and development.
Mr. Daniel P. Van Plew is a prominent executive at Regeneron Pharmaceuticals, Inc., where he serves as the Executive Vice President and General Manager of Industrial Operations and Product Supply. As part of the leadership team, Van Plew plays a crucial role in overseeing the company's manufacturing and distribution operations. His responsibilities include managing Regeneron's large-scale manufacturing facilities, ensuring compliance with regulatory standards, and optimizing supply chain operations to meet global demand for the company's pharmaceutical products. With a strong background in biotechnology and pharmaceuticals, Van Plew joined Regeneron in 2007 and has since been instrumental in scaling up production capabilities, particularly in the context of biologics manufacturing. His leadership has contributed to Regeneron’s reputation for high-quality product supply, enabling the company to effectively respond to the healthcare needs worldwide. Prior to his tenure at Regeneron, Daniel P. Van Plew held positions in various biotechnology and healthcare companies, where he gained extensive experience in operations and management. His educational background and industry expertise have made him a key figure in advancing Regeneron’s operational excellence and maintaining its position as a leader in biopharmaceutical innovation.
With a strong background in biotechnology and pharmaceuticals, Van Plew joined Regeneron in 2007 and has since been instrumental in scaling up production capabilities, particularly in the context of biologics manufacturing. His leadership has contributed to Regeneron’s reputation for high-quality product supply, enabling the company to effectively respond to the healthcare needs worldwide.
Prior to his tenure at Regeneron, Daniel P. Van Plew held positions in various biotechnology and healthcare companies, where he gained extensive experience in operations and management. His educational background and industry expertise have made him a key figure in advancing Regeneron’s operational excellence and maintaining its position as a leader in biopharmaceutical innovation.

Christopher R. Fenimore is a notable executive at Regeneron Pharmaceuticals, Inc., where he currently serves as the Senior Vice President, Head of Accounting and Controller. As a Certified Public Accountant (CPA), he brings a wealth of expertise in financial management and accounting to the company. Fenimore oversees financial reporting, financial planning and analysis, operational finance, and internal controls, ensuring the company's financial integrity and compliance with accounting standards and regulations. His role is critical in supporting Regeneron's financial strategy, and he plays a significant part in helping the company navigate the complex regulatory environment of the pharmaceutical industry. His leadership and financial acumen contribute to Regeneron's ongoing success and expansion in developing innovative medicines. Fenimore's extensive experience in finance and accounting, complemented by his CPA credential, underscores his capability in managing the financial aspects of a major biotechnology firm effectively.

His role is critical in supporting Regeneron's financial strategy, and he plays a significant part in helping the company navigate the complex regulatory environment of the pharmaceutical industry. His leadership and financial acumen contribute to Regeneron's ongoing success and expansion in developing innovative medicines. Fenimore's extensive experience in finance and accounting, complemented by his CPA credential, underscores his capability in managing the financial aspects of a major biotechnology firm effectively.

Ryan Crowe is not publicly recognized or widely documented as an executive at Regeneron Pharmaceuticals Inc. There may be limited or no publicly available information about an individual by that name associated with the company. Please verify the spelling or provide additional context to assist further. If he is a less public figure or in a different role than commonly listed executives, detailed biographical information might not be readily accessible. If you're referring to another individual or require information about a different person at Regeneron, please provide additional details.

If you're referring to another individual or require information about a different person at Regeneron, please provide additional details.
Joseph J. LaRosa is a prominent legal professional known for his leadership and expertise in the pharmaceutical and biotechnology industries. At Regeneron Pharmaceuticals, Inc., he serves as the Executive Vice President, General Counsel, and Secretary. In his role, LaRosa is responsible for overseeing all legal matters pertaining to the company, including regulatory compliance, intellectual property, and corporate governance. Before joining Regeneron, LaRosa accumulated extensive experience in legal affairs, having worked with other major corporations in the healthcare sector. His distinguished career is marked by his ability to navigate complex legal environments and provide strategic counsel that supports the company's innovative efforts and business goals. LaRosa holds a Juris Doctor (J.D.) degree, underlining his profound knowledge and professional credentials in the field of law. His contributions at Regeneron are integral to the company's operations and its commitment to addressing unmet medical needs through innovative research and development.
Before joining Regeneron, LaRosa accumulated extensive experience in legal affairs, having worked with other major corporations in the healthcare sector. His distinguished career is marked by his ability to navigate complex legal environments and provide strategic counsel that supports the company's innovative efforts and business goals.
LaRosa holds a Juris Doctor (J.D.) degree, underlining his profound knowledge and professional credentials in the field of law. His contributions at Regeneron are integral to the company's operations and its commitment to addressing unmet medical needs through innovative research and development.
Melissa Lozner serves as the Executive Vice President, General Counsel, and Secretary at Regeneron Pharmaceuticals Inc. She joined Regeneron in 2019 as Vice President and Associate General Counsel, Regulatory & Litigation, and took on the role of General Counsel in 2022. At Regeneron, Lozner is responsible for overseeing all legal matters, leading the company's legal strategy, and ensuring regulatory compliance. Before her tenure at Regeneron, Lozner gained extensive legal experience at Bristol Myers Squibb, where she held various positions and worked on significant litigation and regulatory issues. Additionally, she previously served in roles at Skadden, Arps, Slate, Meagher & Flom LLP, a prestigious international law firm, where she specialized in litigation and regulatory matters. Lozner holds a J.D. from the University of Pennsylvania Law School and a B.A. from Georgetown University. Her combination of regulatory expertise and legal acumen makes her a significant contributor to Regeneron's leadership team.
Before her tenure at Regeneron, Lozner gained extensive legal experience at Bristol Myers Squibb, where she held various positions and worked on significant litigation and regulatory issues. Additionally, she previously served in roles at Skadden, Arps, Slate, Meagher & Flom LLP, a prestigious international law firm, where she specialized in litigation and regulatory matters.
Lozner holds a J.D. from the University of Pennsylvania Law School and a B.A. from Georgetown University. Her combination of regulatory expertise and legal acumen makes her a significant contributor to Regeneron's leadership team.